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Summary
 
Experimental autoimmune encephalomyelitis (EAE) is an animal model for autoimmune cen-
tral nervous system disease mediated by CD4 T cells. To examine the role of B cells in the in-
duction of EAE, we used B10.PL (I-A
 
u
 
) mice rendered deficient in B cells by deletion of their
 
m
 
 chain transmembrane region (B10.PL
 
m
 
MT). By immunizing B10.PL and B10.PL
 
m
 
MT mice
with the NH-terminal myelin basic protein encephalitogenic peptide Ac1-11, we observed no
difference in the onset or severity of disease in the absence of mature B cells. There was, how-
ever, a greater variation in disease onset, severity, and especially of recovery in the B cell–defi-
cient mice compared to controls. B10.PL
 
m
 
MT mice rarely returned to normal in the absence
of B cells. Taken together, our data suggest that B cells do not play a role in the activation of
encephalitogenic T cells, but may contribute to the immune modulation of acute EAE. The
mechanisms to explain these effects are discussed.
 
E
 
xperimental autoimmune encephalomyelitis (EAE)
 
1
 
 is
a demyelinating disease that is characterized by focal ar-
eas of inflammation and demyelination throughout the cen-
tral nervous system (CNS) (1). The disease is acute or chronic
relapsing with a clinical course characterized by a rapid on-
set of hind limb weakness which commonly progresses to
paralysis, followed by spontaneous remission 7–10 d after
the initial appearance of symptoms. EAE can be actively in-
duced in genetically susceptible animal strains by the injection
of myelin basic protein (MBP) in appropriate adjuvants, and it
is mediated by activated CD4 T cells that are specific for
the encephalitogenic portion of MBP (2–4). Immunization
of the B10.PL mouse strain with MBP or its encephalitoge-
nic NH
 
2
 
-terminal peptide (MBP Ac1-11) emulsified in
CFA leads to the development of acute EAE (5).
Using the B10.PL mouse model, we addressed the need
for B cells in the induction of EAE. Previous reports with the
Lewis rat have shown that EAE could not be induced by
MBP antigen/CFA immunization in animals injected from
birth with anti–rat Ig to eliminate B cells (6). However, it was
later shown that EAE could be induced in B cell–depleted
rats if the animal was also injected with MBP specific antise-
rum (7). In the mouse model, it was reported that mice de-
pleted of B cells with anti-IgM from birth were refractory
to disease induction with MBP antigen/CFA and lacked
secondary T cell proliferative responses in primed LN (8).
In this study, we compared induction of EAE in B10.PL
and B10.PL mice rendered deficient of B cells by disruption
of the 
 
m
 
 heavy chain transmembrane exon (B10.PL
 
m
 
MT)
(9). We show that B10.PL
 
m
 
MT mice have a similar inci-
dence rate of EAE induction when compared to controls.
The B10.PL
 
m
 
MT animals had greater variation in day of
disease onset and disease severity, and they failed to com-
pletely recover as compared to B10.PL in which spontane-
ous recovery was the norm. Our data show that B cells are
not required for the activation of encephalitogenic T cells,
and hence the induction of EAE, but may play a role in the
immune regulation of the course of this disease.
 
Materials and Methods
 
Mice.
 
B10.PL mice (I-A
 
u
 
) were purchased from the Jackson
Laboratory (Bar Harbor, ME), or reared in our colony at Yale
University. C57/BL6 
 
m
 
MT (B cell-deficient) mice were pro-
vided to us by Dr. K. Rajewsky (10), and were backcrossed onto
B10.PL mice for over eight generations and then intercrossed to
generate homozygous B10.PL
 
m
 
MT in our colony at Yale Uni-
versity. All mice were between 2 and 6 mo of age upon use.
 
Peptides and Antibodies.
 
The MBP Ac1-11 (Ac-ASQKRPS-
QRSK) peptide and the HEL 30-53 (CAAKFESNFNTQAT-
NRNTDGSTDY) peptide were synthesized and HPLC purified
by the W.M. Keck Foundation Biotechnology Resource Labora-
tory at Yale University. YCD3.1 (rat anti–mouse CD3), GK1.5 (rat
anti–mouse CD4), 53-6.72 (rat anti–mouse CD8), Y3JP (mouse
anti–mouse I-A), and Y19 (rat anti–mouse Thy1) were purchased
from American Type Culture Collection (Rockville, MD) or
grown locally. Anti–mouse CD4-FITC, anti–mouse CD4-R613,
and anti–mouse CD8-R613 were purchased from GIBCO BRL
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; DC, den-
dritic cell; EAE, experimental autoimmune encephalomyelitis; HPRT,
hypoxanthine-guanine phosphoribosyl transferase; MBP, myelin basic
protein; RT, reverse transcriptase.
  
2272
 
Experimental Autoimmune Encephalomyelitis Induction
(Gaithersburg, MD). Anti–mouse 
 
ab
 
 TCR-PE and anti–mouse
V
 
b
 
8.1,8.2 TCR-FITC were purchased from PharMingen (San
Diego, CA). Anti–mouse polyvalent Ig-FITC was purchased
from Sigma Chemical Co. (St. Louis, MO).
 
Immunofluorescence.
 
Two-color immunofluorescence staining
using anti-TCR 
 
ab
 
-PE and anti-Ig-FITC was carried out on whole
naive spleen cells from B10.PL and B10.PL
 
m
 
MT mice. Three-
color immunofluorescence staining with anti-CD4-FITC, anti-
TCR 
 
ab
 
-PE, and anti-CD8-R613 or anti-TCR V
 
b
 
8.1,8.2-FITC,
anti-TCR 
 
ab
 
-PE, and anti-CD4-R613 was carried out on whole
naive spleen and thymus from B10.PL and B10.PL
 
m
 
MT mice.
Antibody incubations were carried out on ice and the cells were
fixed in 1% paraformaldehyde and analyzed using CellQuest on a
FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
EAE Induction.
 
Groups of four to five B10.PL and B10.PL
 
m
 
MT
female mice were immunized with 150 
 
m
 
g of MBP Ac1-11
emulsified in 100 
 
m
 
l of CFA containing 4 mg/ml of heat-killed
mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit,
MI) subcutaneously in each internal flank. 200 ng of pertussis toxin
(List Biological Labs. Inc., Campbell, CA) in PBS was injected in-
travenously at the time of immunization and again 48 h later.
 
T Cell Activation Assay.
 
CD4
 
1
 
 T cells were isolated from
spleen of B10.PL and B10.PL
 
m
 
MT mice, and 10
 
5
 
 cells in Click’s
modified EHAA medium with 5% FCS (Click’s 5%) were added
to 96-well flat-bottom microtiter plates containing plate-bound
anti-CD3 in serial 1:3 dilutions from 0.1–10 
 
m
 
g/ml. Anti-CD3
diluted in PBS was preabsorbed onto 96-well flat-bottom micro-
titer plates for 1 h at 37
 
8
 
C, and washed three times. Con A stim-
ulation was performed by culturing CD4
 
1
 
 T cells from the spleen
of B10.PL and B10.PL
 
m
 
MT mice at serial 1:3 dilutions from 0.1–
3.0 
 
3
 
 10
 
5
 
 cells/well in the presence of 5 
 
m
 
g/ml Con A (Pharma-
cia CKB Biotechnology Inc., Piscataway, NJ). Cultures were
pulsed after 48 h with 1 
 
m
 
Ci [
 
3
 
H]TdR and harvested after 15–18 h.
Individual data points were set up in triplicate.
 
T Cell Recall Proliferation.
 
B10.PL and B10.PL
 
m
 
MT mice were
immunized with 150 
 
m
 
g Ac 1-11 or HEL 30-53 emulsified in
CFA in the hind foot pads. After 10 d, the popliteal LN were re-
moved and CD4
 
1
 
 cells were isolated by depleting the LN cells of
CD8
 
1
 
 T cells and B cells using anti-CD8 (TIB 105) and Y3JP
(anti-IA), respectively, and magnetic beads. 2 
 
3
 
 10
 
5
 
 CD4
 
1
 
 LN
cells were cocultured with 2 
 
3
 
 10
 
5
 
 irradiated splenic APC iso-
lated from B10.PL mice by depleting T cells with anti-CD4
(GK1.5), anti-CD8 (TIB 105), Thy1 (Y19), and magnetic beads.
Proliferation to Ac 1-11 or HEL 30-53 was detected at 72 h by
adding 1 
 
m
 
Ci [
 
3
 
H]TdR to each well for the last 15–18 h of cul-
ture. CD4
 
1
 
 T cells were 
 
.
 
90% pure.
 
Cytokine mRNA Production.
 
Semi-quantitative reverse tran-
scriptase (RT)-PCR was used to detect cytokine mRNA synthe-
sis from LN cells isolated from B10.PL and B10.PL
 
m
 
MT mice
immunized in the footpads with 150 
 
m
 
g Ac 1-11 or HEL 30-53
emulsified in CFA. After 10 d, the popliteal LN were removed and
CD4
 
1
 
 T cells were isolated as described above. Detection of cy-
tokine mRNA was performed according to Pfeiffer et al. (11) with
modifications. Briefly, 4 
 
3
 
 10
 
6
 
 CD4
 
1
 
 T cells were cocultured
with 2 
 
3
 
 10
 
6
 
 I-A
 
u
 
 irradiated splenic APC (isolated as described
above) in the presence of 100 
 
m
 
g/ml Ac 1-11 or HEL 30-53. After
48 h, cDNA was prepared and PCR amplified for the housekeeping
gene hypoxanthine-guanine phosphoribosyl transferase (HPRT)
with 1 cycle of 94
 
8
 
C for 5 min, 55
 
8
 
C for 1 min, and 72
 
8
 
C for 1 min,
followed by 25–30 cycles of 94
 
8
 
C for 1 min, 55
 
8
 
C for 1 min, and
72
 
8
 
C for 1, min and ending with a final extension at 72
 
8
 
C for 15
min. The PCR reaction for HPRT was used to confirm that equal
amounts of cDNA were used from each cDNA preparation. The
HPRT-PCR products were quantitated using the Is-1000 Digital
Imaging System (Alpha Innotech, Corp., San Leandro, CA). Sub-
sequent PCR reactions were performed using cDNA from 2 
 
3
 
10
 
5
 
 cell equivalents to detect IL-2, IL-4, IFN-
 
g
 
, and TNF-
 
a
 
.
Forward primer for IL-2 was TCCACTTCAAGCTCTA-
CAG; reverse primer was GAGTCAAATCCAGAACATGCC;
PCR product length is 247 bp. Forward primer for IL-4 was
CATCGGCATTTTGAACGAGGTCA; reverse primer was CTT-
ATCGATGAATCCAGGCATCG; PCR product length is 240
bp. Forward primer for IFN-
 
g
 
 was CATTGAAAGCCTAGAA-
AGTCTG; reverse primer was CTCATGAATGCATCCTT-
TTTCG; PCR product length is 267 bp. Forward primer for
HPRT was GTTGGATACAGGCCAGACTTTGTTG; reverse
primer was GAGGGTAGGCTGGCCTATTGGCT; PCR prod-
uct is 352 bp. Forward primer for TNF-
 
a
 
 was GTTCTATGGC-
CCAGACCCTCACA; reverse primer was TCCCAGGTAT-
ATGGGTTCATACC; PCR product length is 383 bp. Bands
were visualized by loading 10 
 
m
 
l of the PCR reaction onto a
1.2% agarose gel, running the gel at 100 V for 1 h, staining for 30
min in 0.5 
 
m
 
g/ml ethidium bromide, and destaining in water.
 
Results
 
B Cell–deficient Mice (B10.PL 
 
m
 
MT) Have Normal Num-
bers of CD4 and CD8 T Cells in Thymus and Spleen, but No
Mature B Cells.
 
To test whether B cells are involved in
the induction or recovery of EAE in mice immunized with
MBP Ac1-11, we generated B10.PL (I-A
 
u
 
) mice deficient
in mature B cells (B10.PL
 
m
 
MT). We backcrossed the EAE
susceptible strain, B10.PL, for 
 
>
 
8 generations with the
 
m
 
MT B cell–deficient mouse (I-A
 
b
 
) provided by Dr. K.
Rajewsky (10), and then intercrossed these F1-backcross
mice to create homozygous B10.PL
 
m
 
MT animals. As shown
in Fig. 1 
 
B
 
, B10.PL
 
m
 
MT mice lack mature Ig expressing B
cells in the spleen, while maintaining an increased percent-
age of T cells as measured by staining for the 
 
ab
 
 TCR.
This is in contrast with the normal B10.PL mice which
contain both B and T cell populations in the spleen (Fig. 1
 
A
 
). We also analyzed the B10.PL
 
m
 
MT mice for the ex-
pression of the B cell specific CD45 isoform, B220, and did
not detect any positive cells (data not shown).
Although spleens from B10.PL
 
m
 
MT have 50–75% lower
total cell numbers than B10.PL control mice, the total
numbers of TCR-CD4
 
1
 
 and TCR-CD8
 
1
 
 cells are similar
(Table 1). Likewise, the total cell numbers in the thymus of
B10.PL and B10.PL
 
m
 
MT mice are also similar (Table 1).
These observations are in agreement with a similar analysis
described by Epstein et al., which used B6
 
m
 
MT mice (12).
We also examined CD4
 
1
 
 T cells in the spleen and thymus
for the usage of the V
 
b
 
8.2 TCR because this population of
T cells is the predominant encephalitogenic cell in I-A
 
u
 
 mouse
strains (13, 14). As shown in Table 1, both B10.PL and
B10.PL
 
m
 
MT have a prominent population of CD4
 
1
 
,
V
 
b
 
8.2
 
1
 
 T cells in both the thymus and spleen. The pres-
ence of CD4
 
1
 
,V
 
b
 
8.2
 
1
 
 cells in the spleen confirms that
there is no defect in the selection and exportation from the
thymus of these cells in our B10.PL
 
m
 
MT mice.
Naive T Cells in the B10.PLmMT Mice Can Be Activated
by Anti-CD3 and Con A. Since T cells in both B10.PLmMT2273 Wolf et al.
and B10.PL mice are quantitatively similar, we examined
whether functional differences in T cell activation could be
detected in T cells from B10.PL and B10.PLmMT mice.
Naive CD41 T cells were isolated from the spleen of
B10.PL and B10.PLmMT mice and stimulated using plate-
bound anti-CD3 or soluble Con A. As shown in Fig. 2 A,
proliferation to anti-CD3 in both B10.PL and B10.PLmMT
mice as measured by [3H]TdR incorporation was identical
and occurred in a dose-dependent manner. Similarly, naive
CD41 T cells from the B10.PLmMT mice responded as
well as wild-type T cells to Con A activation in a cell dose–
dependent manner (Fig. 2 B). These data demonstrate that
T cells in the B10. PLmMT mice are functionally intact
and can be activated through conventional activation path-
ways.
B10.PL and B10.PLmMT Mice Immunized with MBP
Ac1-11 Have a Th1 Recall Response. To examine the cy-
tokine profile induced in response to MBP Ac1-11, we im-
munized B10.PL and B10.PLmMT mice with MBP Ac1-11
and the control peptide HEL 30-53. After 10 d, we isolated
CD41 T cells from the popliteal LN and measured the re-
call response to MBP Ac1-11 and HEL 30-53. As shown in
Fig. 3 A, CD41 T cells from both the B10.PL normal and
B10.PLmMT mice proliferated in response to MBP Ac1-11
in a dose-dependent manner, as measured by [3H]TdR in-
corporation. Similarly, as shown in Fig. 3 B, both B10.PL
and B10.PLmMT mice also responded well when chal-
lenged with the control I-Au binding peptide HEL 30-53.
However, unlike the response to MPB Ac 1-11, the re-
sponse to HEL 30-53 was lower in the B10.PLmMT mice
when compared to the B10.PL normal mice.
Because EAE has been shown to be mediated by T cells
with a Th1 cytokine response indicative of the disease
phase and a Th2 cytokine response associated with the re-
covery phase of EAE, we analyzed primed CD41 LN cells
for cytokine production following in vitro stimulation with
Ac1-11 or HEL 30-53. Using semi-quantitative RT-PCR,
transcripts for the Th1 cytokines IFN-g, TNF-a, and IL-2
were detected in both B10.PL and B10.PLmMT mice im-
munized with MBP Ac1-11 or HEL 30-53 (Fig. 3 C). We
did not detect mRNA transcripts for the Th2 cytokines IL-4
(Fig. 3 C) or IL-5 (data not shown), nor for the cytokines
TGF-b1 or TGF-b2 (data not shown). However, faint
transcripts for IL-10 were detected from all mice analyzed
(data not shown). We used the Th2 D10 clone and the
Th1 D10.TCR 25 clone (11) which respond to peptide
134-146 of hen egg conalbumin (CA 134-146) in the con-
text of I-Ak as controls for Th2 and Th1 cytokine re-
sponses. As shown in Fig. 3 C, the D10 clone produced
mRNA transcripts for the Th2 cytokine IL-4, but not Th1
cytokines, while D10.TCR 25 produced transcripts only
for the Th1 cytokines IFN-g and TNF-a.
EAE Is Inducible in B10.PLmMT Mice Using MBP Ac1-11
With No Observable Differences in Disease Onset or Disease Se-
verity, but Highly Significant Differences in Spontaneous Recov-
ery as Compared to Wild-type Animals. Since B10.PLmMT
mice have normal T cell function and lack mature B cells, we
used these mice to examine the previously reported require-
Figure 1. Two-color dot plots of Ig and
TCR ab expression on spleen cells from
B10.PL and B10.PLmMT mice. Spleen cells
were stained for the expression of Ig (x-axis)
and ab TCR (y-axis). Data represent analy-
sis performed on male age matched B10.PL
(A) and B10.PLmMT (B) mice from one of
five sets of experiments each with similar re-
sults.
Table 1. Comparison of T Cell Populations in B10.PL and B10.PLmMT Mice*
Total cells
(3106)
TCR-CD41 cells
(3106)
TCR-CD81 cells
(3106)
Vb8.2-CD1 cells
(%)‡
B10.PL Spleen 125 19.0 9.5 12.7
Thymus 100 10.5 3.4 2.0
B10.PLmMT Spleen 40 14.6 6.1 13.7
Thymus 150 16.2 3.6 2.3
*The data is from one of five experiments, each with similar results.
‡The percent of Vb8.2-CD41 cells is derived from the TCR-CD41 cell population.2274 Experimental Autoimmune Encephalomyelitis Induction
ment for B cells in the induction and recovery from peptide-
induced EAE. We immunized B10.PL and B10.PLmMT
mice with 150 mg MBP Ac1-11 emulsified in CFA in the
flanks combined with the intravenous injection of pertussis
toxin. We successfully used this immunization protocol to
induce EAE with a peak incidence in normal mice at 16.2 6
0.68 d. We were also able to induce disease in B10.
PLmMT with a peak incidence at 15.4 6 0.92 d (Table 2,
Fig. 4). In the B10.PLmMT mice, initial signs of disease
were noticed as early as day 9 and as late as day 25 after im-
munization, compared to the B10.PL group which had a
smaller range of EAE onset, days 13–21. The variation in
disease onset was not significantly different in the two
groups of animals. In addition, B10.PLmMT and B10.PL
mice have a similar incidence of EAE induction, with a to-
tal of 19/22 B10.PLmMT animals demonstrating symptoms
associated with EAE as compared to 16/19 B cell sufficient
B10.PL mice. Likewise, when the average disease severity
was analyzed (rated on a sliding scale from 0 to 5, ranging
from no disease to death), no difference was detected be-
tween B10.PL and B10.PLmMT mice (Table 2). However,
it was observed that individual B10.PLmMT as compared
to wild type achieved a higher grade of disease severity
(Fig. 4, B and C).
By day 40, spontaneous recovery reached a plateau in both
groups, and it was consistently observed that B10.PLmMT
animals did not recover completely in comparison to wild-
type controls (Fig. 4 A–C). The average clinical grade in B
cell–deficient mice was 2.03 6 0.20 compared to 0.44 6
0.14 in wild-type animals, which is a statistically significant
difference (P 5 0.01). The variability of individual mice
with respect to the range of disease onset, severity, and re-
covery between the two groups is represented in Fig. 4, B
and C. Our data show that the B cell–deficient B10.PLmMT
mice are just as susceptible to the peptide induction of
EAE, but differ in the various degrees of disease severity
and in the ability to completely recover. Thus, although B
cells are not necessary for the induction of EAE, they may
Figure 2. Proliferation of CD41 T cells from
B10.PL and B10.PLmMT mice in response to Con A
and anti-CD3. CD41 spleen cells from one B10.PL
mouse (open square) and one B10.PLmMT mouse
(closed circle) were cultured in the presence of 1:3 dilu-
tions of plate-bound anti-CD3 from 10 to 0.12 mg/
ml (A) or 1:3 dilutions of CD41 T cells from 0.1 to
3.0 3 105 cells/well in the presence of 5 mg/ml Con
A (B). Proliferation was measured by [3H]TdR incor-
poration and is presented as CPM performed in du-
plicate. Data in A and B are from the same mice with
identical animals sharing symbols and represents one
third of the experiments, each with similar results.
Figure 3. Proliferation of CD41 LN cells from B10.PL and B10.PLmMT mice immunized with MBP Ac 1-11 (A) or HEL 30-53 (B). CD41 LN cells
from B10.PL (open squares) and B10.PLmMT (closed circles) were isolated as described in the Material and Methods from the popliteal LN of mice immu-
nized in the footpads with 150 mg MBP Ac1-11 or HEL 30-53 10 d before, and cocultured with splenic APC in the presence of 1:5 dilutions of MBP
Ac1-11 or HEL 30-53 from 100 to 0.16 mg/ml. Background proliferation in the absence of stimulating peptide was subtracted from each data point and
is shown as zero on the proliferation curves and was less than 10,000 cpm. Proliferation was measured by [3H]TdR incorporation and presented as counts
per minute performed in duplicate. (C) CD41 LN cells from the identical mice used in A and B were incubated with splenic APC as described in the
Material and Methods in the presence of 100 mg/ml MBP Ac1-11 or HEL 30-53. After 48 h, total cellular RNA was isolated from 3.2 3 106 cells. RT-PCR
was then performed using primers for HPRT and the HPRT product was quantitated to ensure equal levels of cDNA used in subsequent PCR reactions.
PCR was then performed using cDNA from 2 3 105 cell equivalents for IL-2, IL-4, IFN-g, and TNF-a for 30 cycles. The HPRT-PCR reaction was
performed with 25 cycles. D10, a Th2 clone, was used as a positive control for IL-4, and D10.TCR 25, a Th1 clone, was used as a positive control for
IL-2, IFN-g, and TNF-a.2275 Wolf et al.
play a role in the immune regulation required of animals
to completely recover from the limb paralysis characteristic
of EAE.
Discussion
We have examined the role of B cells in the induction of
EAE. We found that in the absence of B cells, EAE could be
induced in mice. In contrast to the results we have obtained
in our genetically B cell–deficient mouse model, previous
studies in rat and murine models reported that EAE induc-
tion did not occur in B cell–depleted animals (6, 8). How-
ever, two important differences exist between our B cell–
deficient mice and those previously used. First, the earlier
B cell–deficient animals were obtained by depletion of B
cells with infusion of anti-IgM antibodies in neonatal ani-
mals. Our mice were generated by targeted disruption of
the IgM heavy chain gene transmembrane region, which
Table 2. Induction of EAE and Spontaneous Recovery*
B10.PL B10.PLmMT P**
Incidence 16/19‡ 19/22
Onset day of EAE 16.2 6 0.68 (13-21)§ 15.4 6 0.92 (9-25) P 5 NS
Maximum disease severity 2.47 6 0.21 (1-3.5)i 2.66 6 0.20 (1.5-5) P 5 NS
Disease at day 40 0.44 6 0.14 (0-1)¶ 2.03 6 0.20 (1-5) P 5 0.01
*B10.PL and B10.PLmMT female mice were inoculated with MBP Ac1-11 emulsified in CFA and observed for signs of EAE.
‡3/19 B10.PL mice and 3/22 B10.PLmMT mice inoculated with MBP Ac1-11 did not show signs of EAE. These animals were not included in the
following statistics (§ i ‡ **).
(i ¶)Mean 6 SE (range).
EAE disease severity was graded in a scale 0–5: 0, no disease; 1, limp tail; 2, hind limb paresis; 3, hind limb paralysis; 4, hind limb and fore limb pa-
ralysis; 5, death.
All animals were graded daily through day 40.
**Student’s t test using 34 degrees of freedom was applied to the two groups. P <0.01 is considered significant.
Figure 4. Comparison of EAE
clinical course in B10.PL versus
B10.PLmMT mice. B10.PL and
B10.PLmMT mice were immunized
with 150 mg MBP Ac1-11 in the
flanks and intravenously injected
with pertussis toxin on the day of
immunization, and again 48 h later.
The individual mice were scored
for the severity of EAE using the
following scale: 0, no disease; 1, limp
tail; 2, hind limb paresis; 3, hind
limb paralysis; 4, hind and fore
limb paralysis; 5, death. Mice were
examined daily from day 8 to 40,
and the daily score from all B10.PL
mice (open squares) and B10.PLmMT
mice (closed circles) that developed
signs of clinical disease were aver-
aged (A). The data in A represents
the average of 16/19 B10.PL mice
and 19/22 B10.PLmMT mice that
manifested disease. Data from indi-
vidual mice were plotted from three
consecutive B10.PL (squares) (B)
and four consecutive B10.PLmMT
(circles) (C) mice. The data was col-
lected from one fifth of the experi-
ments set up.2276 Experimental Autoimmune Encephalomyelitis Induction
prevents the development of mature B cells (10). Our
model has the advantage of eliminating any possibility of B
cell leakage or unknown deleterious effects on other APC
from infusion of exogenous protein. Second, in previous
experiments, EAE induction was attempted using whole
MBP emulsified in CFA for immunization or injections of
mouse spinal cord homogenized in CFA. In these experi-
ments, we immunized with a peptide antigen, MBP Ac1-11
in CFA. However, preliminary results from our lab show
that B10.PLmMT mice develop EAE using whole mouse
MBP as antigen and also that isolated CD41 T cells from
spleen taken at day 40 from these mice proliferate to the en-
cephalitogenic peptide MBP Ac1-11 (our unpublished data).
Our results are in concordance with recently published
data by other investigators who showed that efficient in
vivo priming of T cells (as measured by proliferation to re-
call antigen), to peptide, and to some proteins occurs in
genetically B cell–deficient mice (12, 15, 16). Our results
are also in agreement with Sunshine’s results showing
that T cells can be primed in SCID mice in the absence of
B cells (17). The B10.PLmMT (I-Au) strain used in our ex-
periments has the benefit of demonstrating for the first time
that the lack of B cells has no impact on the in situ function
of primed CD41 T cells, measured in our model by the
ability of encephalitogenic T cells to become activated and
to induce EAE.
Our data support the hypothesis that the initiating APC
in immune responses to peptide antigens is most likely the
dendritic cell (DC). DCs efficiently take up, process, and
present soluble protein, and can stimulate naive T cells
more efficiently than do B cells or macrophages (18–21).
Recently, Guery et al. demonstrated that antigen com-
plexes capable of activating T cell hybridomas are expressed
only by LN-DC, and not B cells, after subcutaneous ad-
ministration of protein antigen in adjuvant (22). Though
their data strongly support the hypothesis that DC, and not
B cells, are required for stimulating unprimed T cell prolif-
erative responses in vivo (20, 23–27), other investigators
have generated data supporting the ability of activated B cells
to stimulate naive T cells (18, 28–33).
Lin et al. (34) proposed a model in which dendritic cells
prime the first cohort of native T cells, which then provide
help for the activation of B cells. Once activated, the B cells
can then directly prime additional naive T cells (34–36).
The variability we observed in our mice with respect to
disease onset, severity, and spontaneous recovery (Fig. 4, B
and C) could be interpreted using Lin’s model in conjunc-
tion with the Th1–Th2 immune deviation hypothesis for
inflammatory autoimmune disease (37, 38).
It is known that EAE is mediated by CD4 T cells secret-
ing the Th1 cytokines IL-2, INF-g, TNF-a, and lympho-
toxin, and once activated, these encephalitogenic T cells
express a4 integrin on their cell surface which is required
for entry into the CNS (39). Furthermore, it has been shown
that T cells producing the Th2 cytokines IL-4, IL-10, and
TGF-b1 interact with and regulate Th1 T cells in EAE
(40–42). Several pieces of evidence suggest B cells acting as
APC, skew T helper cells to differentiate toward a Th2 re-
sponse (35, 38, 43–46). The lack of spontaneous recovery
observed in our B10.PLmMT mice could be due to the
lack of B cells acting as APCs for Th2 cells. An absence of
Th2 cytokines may allow continued expansion and migra-
tion of activated Th1 encephalitogenic cells into the CNS,
thus prolonging inflammation and demyelination in the
target organ and hence, preventing complete recovery. We
are currently investigating this possibility by using the RT-
PCR method to examine Th1 and Th2 cytokine produc-
tion in LN cells and spleen, while simultaneously examin-
ing CNS histology for the presence of CD41Vb8.21 cells
in the B10.PLmMT and comparing this to B10.PL mice at
multiple time points during the disease course.
In this study, we introduced a mouse model genetically
deficient in B cells and susceptible to EAE. We demon-
strated that B cells are not necessary for activating MBP
Ac1-11–specific encephalitogenic T cells, and that the ab-
sence of B cells does not impair the resulting T cell effector
functions. These results are in contrast to previous studies
which showed impairment of T cell function in normal
mice depleted of B cells by neonatal treatment with anti-
IgM antibodies. This difference may be explained by the
antigen-presenting property of the remaining endogenous
APCs, having been disrupted by the process of B cell deple-
tion used (47–51). An additional finding in this study was the
observation that the spontaneous recovery in B10.PLmMT
mice was incomplete and heterogeneous as compared to
B10.PL controls. We propose that B cells may play a role
in immune regulation in EAE through immune deviation
from Th1 to Th2 cytokines (37), possibly by altering pep-
tide dose, complexity, or costimulator expression (52). How-
ever, other possibilities also exist. For instance, B cells could
present peptides of the T cell receptor in the context of I-Au,
which are not found on T cells in mice. Because T cells
have been reported to protect against EAE, to be induced
during disease, and to contribute to recovery (53), this is
also possible.
In conclusion, our genetically B cell–deficient model
gives us the opportunity to contribute to the understanding
of the complex cellular interactions that are responsible for
EAE, and perhaps for human autoimmune diseases such as
multiple sclerosis as well.
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